ArticleTheranostics2020
Engineering Circulating Tumor Cells as Novel Cancer Theranostics.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- From spectroscopic analysis to clinical imaging: emerging applications and persistent challenges of raman spectroscopy in CTCs-based liquid biopsies.Annals of medicine · 2026Review
- Bridging In Vitro and Murine Breast Cancer Models: Advanced Imaging Across Multiscale Experimental Platforms.Cancers · 2026Review
- Endogenous living adjuvants for cancer vaccination: Concepts, mechanisms, and design principles.Materials today. Bio · 2026Article
- A Comparison of the Sensitivity and Cellular Detection Capabilities of Magnetic Particle Imaging and Bioluminescence Imaging.Tomography (Ann Arbor, Mich.) · 2024Article
- Current biological implications and clinical relevance of metastatic circulating tumor cells.Clinical and experimental medicine · 2024Review
- Circulating tumor cells: from new biological insights to clinical practice.Signal transduction and targeted therapy · 2024Review
- Cancer metastases: Tailoring the targets.Heliyon · 2024Review
- Recent Advances in the Biomedical Applications of Functionalized Nanogels.Pharmaceutics · 2022Review
- A Human-derived Dual MRI/PET Reporter Gene System with High Translational Potential for Cell Tracking.Molecular imaging and biology · 2022Article
- Applications of Magnetic Particle Imaging in Biomedicine: Advancements and Prospects.Frontiers in physiology · 2022Review
- Safe harbor-targeted CRISPR-Cas9 homology-independent targeted integration for multimodality reporter gene-based cell tracking.Science advances · 2021Article
- Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.Cellular and molecular life sciences : CMLS · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New ways to target and treat metastatic disease are urgently needed. Tumor "self-homing" describes the recruitment of circulating tumor cells (CTCs) back to a previously excised primary tumor location, contributing to tumor recurrence, as well as their migration to established metastatic lesions. Recently, self-homing CTCs have been exploited as delivery vehicles for anti-cancer therapeutics in preclinical primary tumor models. However, the ability of CTCs to self-home and treat metastatic disease is largely unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.